Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001778-17
    Sponsor's Protocol Code Number:201190ZOSTER-049
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-28
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-001778-17
    A.3Full title of the trial
    A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses on a 0 or 0, 2-month schedule in two subgroups of older adults.
    Studio clinico di fase IIIb, multi-paese, multicentrico, in aperto, di follow-up a lungo termine (ZOE-LTFU) degli studi 110390 e 113077 (ZOSTER-006/022), volto a valutare l’efficacia profilattica, la sicurezza e la persistenza dell’immunogenicità del vaccino contro l’herpes zoster (HZ/su) di GSK Biologicals e la valutazione di 1 o 2 dosi aggiuntive secondo uno schema a 0 o a 0, 2 mesi in due sottogruppi di adulti di età avanzata.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A long-term follow-up study (ZOE-LTFU) of two studies 110390 (ZOSTER- 006) and 113077 (ZOSTER-022) to assess the efficacy, safety, and
    immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses in two subgroups of older adults.
    Studio di follow-up a lungo termine (ZOE-LTFU) degli studi 110390 e 113077 (ZOSTER-006/022), volto a valutare l’efficacia, la sicurezza e la persistenza dell’immunogenicità del vaccino contro l’herpes zoster (HZ/su) di GSK Biologicals e la valutazione di 1 o 2 dosi aggiuntive in due sottogruppi di adulti di età avanzata.
    A.3.2Name or abbreviated title of the trial where available
    ZOSTER-049 EXT: 006-022
    ZOSTER-049 EXT: 006-022
    A.4.1Sponsor's protocol code number201190ZOSTER-049
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGLAXOSMITHKLINE BIOLOGICALS
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlaxoSmithKline Biologicals
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Biologicals
    B.5.2Functional name of contact pointClinical Disclosure Advisor
    B.5.3 Address:
    B.5.3.1Street AddressRue de l'institut 89
    B.5.3.2Town/ cityRixensart
    B.5.3.3Post code1330
    B.5.3.4CountryBelgium
    B.5.4Telephone number00442089904466
    B.5.5Fax number00442089904466
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameHerpes Zoster vaccines (GSK 1437173A)
    D.3.2Product code [HZ/su]
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codegE
    D.3.9.3Other descriptive nameRecombinant Varicella Zoster Virus Surface Glycoprotein E
    D.3.9.4EV Substance CodeSUB31416
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination)
    Vaccinazione contro l'Herpes Zoster e le sue relative complicazioni in pazienti ultracinquantenni (al tempo della vaccinazione iniziale)
    E.1.1.1Medical condition in easily understood language
    Herpes zoster (Shingles) disease
    Malattia Herpes Zoster (Fuoco di Sant'Antonio)
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10019982
    E.1.2Term Herpes zoster NOS
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the Vaccine Efficacy (VE) in the prevention of Herpes Zoster (HZ) over the total duration of the ZOSTER-049 (Z49) study overall as measured by the reduction in HZ risk in subjects =50 years of age overall at the
    time of first vaccination in the ZOSTER-006/022 (Z6/22) studies.
    Valutare l’efficacia del vaccino (VE) nel prevenire l’Herpes Zoster durante l’intera durata dello studio ZOSTER-049 (Z49), nel complesso misurata come la riduzione del rischio di sviluppare un caso di HZ nei soggetti di età =50 anni a partire dalla prima vaccinazione ricevuta negli studi ZOSTER-006/022 (Z6/22).
    E.2.2Secondary objectives of the trial
    VEinHZprev.insubjectsofeachage*:
    1 During Z49 VE in HZ prevention in subjects =50Y&*:
    2 From 1 M p-D2 in Z6/22 to Z49 end
    3 Over each Y from 1 M p-D2 in Z6/22
    VE in PHN prev. in sub.=50 Y&*:
    4 Dur.Z49
    5 From 1M p-D2 in Z6/22 to Z49 end
    VE in prev. HZ related compl.(other than PHN) in =50Y &*
    6 From D1 in Z6/22
    7 From 1 M p-D2 in Z6/22 to Z49 end
    I at Y 5-10 & beyond Z6/22 p-1' vacc. in =50Y &*:
    8 HI
    9 CMI
    I at Y 5-10 & beyond Z6/22 p-1' vacc. in =50Y with conf. HZ:
    10 HI
    11 CMI
    I at 1 M p-1st additional HZ/su D (1AdD** & Rev & Ctrl):
    12 HI
    13 CMI
    I at 1 M p-2nd additional HZ/su D (Rev & Ctrl)::
    14 HI
    15 CMI
    I at Y 1-6 of Z49 (1AdD, Rev & Ctrl):
    16 HI
    17 CMI
    18 Safety & reacto (1AdD & Rev)
    19 Safety (LTFU & Ctrl)
    *Ages: 50-59, 60-69, =60 & =70 Y at Day 1 in Z6/22.
    Y=year; M=Month D=Dose; p-=post; 1'=primary; I=Immuno; HI=Humoral Immuno; CMI=Cell-Mediated Immuno.
    **Groups: 1AdD=1-Additional Dose; Rev=Revaccination; Ctrl=Control.

    **Groups: 1AdD=1-Additional Dose; Rev=Revaccination;
    VEnelprev.HZinsoggettidiciascunaetà*:
    1 Z49 VE nel prev. HZ in soggetti =50 A e*:
    2 Da m.1 p-d 2 in Z6/22 a fine Z49
    3 Dopo ogni A dal m. 1 p-D2 in Z6/22
    VEprev. PHN in sogg. =50 A e*:
    4 Dur.Z49
    5 Da m. 1 p-dose 2 in Z6/22 a fine Z49
    VE in prev. compl. HZ correlate in soggetti =50 A e*:
    6 Da g. 1 in Z6/22
    7 Da m. 1 p-D2 in Z6/22 a fine Z49
    I A. 5-10 e oltre Z6/22 p-1 vacc. in soggetti =50 A e*:
    8 HI
    9 CMI
    I A. 5-10 e oltre Z6/22 p-1 vacc. in soggetti =50 A con HZ conf.:
    10 HI
    11 CMI
    I 1 m. p-1 dose agg. HZ su (1Ag** e Riv e Ctrl):
    12 HI
    13 CMI
    I 1 m. p-2 dose aggiuntiva HZ su (Riv e Ctrl):
    14 HI
    15 CMI
    I A. 1-6 di Z49 (1Ag** e Riv e Ctrl)
    16 HI
    17 CMI
    18 Sicurezza e reattogenicità (1Ag e Riv)
    19 Sicurezza (LTFU e Ctrl)
    *Fascie d’età: 50-59, 60-69, =60 e =70 anni al giorno 1 in Z6/Z22
    A=Anno; M=Mese; D=Dose, p-=post 1'=prima vaccinazione; I=Immuno HI=immunogenicità CMI= immunità cellulo-mediata
    **Gruppi: 1Ag: 1 Dose Agg. Riv=Rivaccinazione; Ctrl=Controllo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, ability to have scheduled contacts to
    allow evaluation during the study). Or subjects with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards,
    availability for follow-up contacts);
    •Witten informed consent obtained from the subject prior to performance of any study specific procedure;
    •Subject who participated in ZOSTER-006 or ZOSTER-022 studies and received at least one dose of HZ/su vaccine.
    Soggetti che, a parere dello sperimentatore, possono risultare e risulteranno conformi ai requisiti del protocollo (ossia compilazione delle schede diario, presentazione alle visite di follow-up, capacità di eseguire i contatti programmati per consentire la valutazione durante lo studio). Oppure caregiver dei soggetti che, a parere dello sperimentatore, siano capaci e desiderosi di osservare quanto richiesto dal protocollo di studio (ossia, compilazione delle schede diario, visite per le vaccinazioni, disponibilità per i contatti durante il follow-up).
    Consenso informato scritto fornito dal soggetto prima di eseguire qualsiasi procedura specifica dello studio.
    Soggetto che ha preso parte allo studio ZOSTER-006 o ZOSTER-022 e ha ricevuto almeno una dose del vaccino HZ/su.
    E.4Principal exclusion criteria
    •Use of any investigational or non-registered product (pharmaceutical product or device) at the time of enrolment or planned use during the study period;
    •Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than the HZ/su vaccine administered in studies ZOSTER-006/022);
    •Chronic administration (defined as > 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting six months prior to Visit Month 0 of study ZOSTER-049 or expected administration at any time during the study period. For corticosteroids, this will mean prednisone = 20 mg/day or equivalent. A prednisone dose of < 20 mg/day is allowed. Inhaled, topical and intraarticular corticosteroids are allowed;
    •Administration of long-acting immune-modifying drugs (e.g., infliximab, rituximab) within 6 months prior to Visit Month 0 of study ZOSTER-049 or expected administration at any time during the study
    period;
    •Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., malignancy, human immunodeficiency virus [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders);
    •Administration of immunoglobulins and/or any blood products within 3 months prior to Visit Month 0 of study ZOSTER-049 or planned administration during the study period;
    •Prolonged use (> 14 consecutive days) of oral and/or par-enteral antiviral agents that are active against VZV (acyclovir, valacyclovir, famciclovir, etc. ) and planned to be used during the study period for an indication other than to treat suspected or confirmed HZ or an HZ related complication (topical use of these antiviral agents is allowed).
    •Important underlying illness that in the opinion of the investigator would be expected to interfere significantly during the study;
    • Utilizzo di un qualsiasi farmaco o vaccino sperimentale o non registrato al momento dell’arruolamento o uso programmato durante lo studio.
    • Precedente vaccinazione e/o programmata durante lo studio, contro l’HZ o contro la varicella o, somministrazione di un vaccino anti-HZ o anti-varicella, anche sperimentale o non registrato, diverso dal vaccino di studio.
    • Somministrazione cronica (definita come maggiore di 14 giorni consecutivi) di farmaci immunosoppressori o di altri farmaci immuno-modulatori nei 6 mesi precedenti la prima visita dello studio ZOSTER-049 (Mese 0) o la somministrazione programmata in qualunque momento dello studio. Per i corticosteroidi, si intende prednisone in dose = 20 mg/die o equivalente. Sono consentiti corticosteroidi per uso inalatorio topico e intra-articolare.
    • Somministrazione di farmaci immuno-modulatori con azione a lunga durata (ad es. infliximab, rituximab) nei sei mesi precedenti la visita del mese 0 dello studio Zoster-049, o somministrazione prevista in qualsiasi momento dello studio.
    • Qualsiasi condizione di immunodeficienza o di immunosoppressione, confermata o sospetta, derivante da patologie (ad es. neoplasia maligna, infezione da virus dell’immunodeficienza umana [HIV]) o da terapia immunosoppressiva/citotossica (ad es. farmaci utilizzati durante la chemioterapia oncologica, per i trapianti d’organo o per il trattamento di malattie autoimmuni).
    • Somministrazione di immunoglobuline e/o qualunque prodotto ematico nei 3 mesi precedenti la visita del mese 0 dello studio ZOSTER-049, o somministrazione prevista in qualsiasi momento dello studio.
    • Uso prolungato (>14 giorni consecutivi) di agenti antivirali a somministrazione orale e/o parenterale che sono attivi contro VZV (aciclovir, valaciclovir, famciclovir, ecc.) e, programmati per essere utilizzati, in qualsiasi momento dello studio, per un’indicazione diversa dal trattamento di un caso di HZ sospetto o confermato o di una complicanza ad esso correlato (l’uso topico di questi agenti antivirali è consentito).
    • Un’importante malattia che, a parere dello sperimentatore, potrebbe interferire in modo significativo durante lo studio.
    E.5 End points
    E.5.1Primary end point(s)
    Number of confirmed HZ cases.
    A suspected case of HZ can be confirmed in two ways:
    •By Polymerase Chain Reaction (PCR)
    •By the HZ Ascertainment Committee (HZAC)
    Numero di casi confermati di HZ.
    Un sospetto caso di HZ può essere confermato in due modi:
    • Mediante reazione a catena della polimerasi (PCR)
    • Mediante Comitato di Accertamento di HZ (HZAC)
    E.5.1.1Timepoint(s) of evaluation of this end point
    During the entire study period (up to Month 72)
    Durante l'intero periodo di studio (fino al Mese 72)
    E.5.2Secondary end point(s)
    1. Number of confirmed HZ cases.
    A suspected case of HZ can be confirmed in two ways:
    •By Polymerase Chain Reaction (PCR)
    •By the HZ Ascertainment Committee (HZAC)
    2. Number of Post-Herpetic Neuralgia (PHN) cases defined by the presence of HZ-associated severe 'worst' pain persisting or appearing more than 90 days after onset of the HZ rash.
    ; 3. Number of HZ related complications (other than PHN including HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke).; 4. Anti-glycoprotein E (gE) antibody (Ab) concentrations expressed as geometric mean concentrations (GMCs), as determined by ELISA.

    5. Cell mediated immunogenicity in terms of frequencies of antigen- specific CD4+ T cells (Frequencies of CD4+ T cells with antigen-specific Interferon gamma (IFN-¿) and/or Interleukin-2 (IL-2) and/or Tumour Ne-crosis Factor alpha (TNF-a) and/or CD40 Ligand (CD40L) secretion/expression to gE as determined by ICS).
    ; 6. Number of subjects with any, and Grade 3 solicited local symptoms These symptoms were assessed in subjects administered with 1 or 2 additional doses of HZ/su vaccine. Assessed solicited local symptoms were pain, redness and swelling. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    7. Number of subjects with any, Grade 3 and related solicited general symptoms assessed in subjects administered with 1 or 2 additional doses of HZ/su vaccine. Assessed solicited general symptoms were fatigue, fever [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)], gastrointestinal symptoms, headache, myalgia, and shivering. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
    ; 8. Number of subjects with unsolicited adverse events (AEs) assessed in subjects administered with 1 or 2 additional doses of HZ/su vaccine. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.; 9. Number of subjects with any Serious adverse events (SAEs) assessed including medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    11. Number of subjects with any and related Potential immune-mediated diseases (pIMDs) that are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.; 10. Number of subjects with any SAEs related to investigational vaccine, related to study participation or to GSK concomitant medication/vaccine including medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
    1.Numero di casi confermati di HZ. Un sospetto caso di HZ può essere confermato in due modi:
    • Mediante reazione a catena della polimerasi (PCR)
    • Mediante Comitato di Accertamento di HZ (HZAC)
    2.Numero di casi di Nevralgia Post-Erpetica (PHN) definiti dalla presenza di dolore severo "acuto" associato a HZ che persise o che compare oltre i 90 giorni dall'inizio dell'eruzione di HZ.; 3. Numero di complicanze correlate all'HZ (diverse dalla PHN comprendenti vasculite da HZ, malattia disseminata, malattia oftalmica, malattia neurologica, malattia viscerale o ictus).; 4.Concentrazioni di Anticorpo (Ab) Anti-glicoproteina (gE) espresse come media geometrica delle concentrazioni (GMCs), come determinato dal test ELISA.

    4. Concentrazioni di Anticorpo (Ab) Anti-glicoproteina (gE) espresse come media geometrica delle concentrazioni (GMCs) come determinato dal test ELISA.

    5.Immunogenicità cellulo-mediata in termini di frequenze di cellule T CD4+ antigene-specifiche (frequenze di cellule T CD4+ con secrezione/espressione antigene-specifica di interferone gamma (IFN-y) e/o interleuchina-2 (IL-2) e/o fattore di necrosi tumorale alfa (TNF-a) e/o ligando CD40 (CD40L) nei confronti della gE, determinate mediante colorazione intracellulare delle citochine (ICS).; 6. Numero di soggetti con sintomi locali sollecitati fino al Grado 3. Questi sintomi sono stati determinati in soggetti ai quali sono state somministrate 1 o 2 dosi aggiuntive di vaccino HZ/su. I sintomi locali sollecitati determinati includono dolore, rossore e gonfiore. Dolore di Grado 3 = dolore che previene la normale attività. Rossore/gonfiore di Grado 3 = rossore/ gonfiore che si diffonde oltre 100 millimetri (mm) dal sito di iniezione.

    7. Numero di soggetti con sintomi generali sollecitati e correlati fino al Grado 3 determinati in soggetti ai quali sono state somministrate 1 o 2 dosi aggiuntive di vaccino HZ / su. I sintomi generali sollecitati valutati includono affaticamento, febbre [definita come temperatura orale uguale o superiore a 37,5 gradi Celsius (° C)], sintomi gastrointestinali, mal di testa, mialgia e brividi. Sintomo di Grado 3 = sintomo che previene la normale attività. Febbre di Grado 3 = febbre> 39,0 ° C. Correlato = sintomo valutato dallo sperimentatore come correlato con la vaccinazione.; 8. Numero di soggetti con eventi avversi (AE) spontanei determinati in soggetti ai quali sono state somministrate 1 o 2 dosi aggiuntive di vaccino HZ/su. Un AE spontaneo include qualsiasi evento medico indesiderato in un soggetto di indagine clinica temporalmente associato all'uso di un prodotto medicinale, indipendentemente dal fatto che sia considerato correlato o meno al prodotto medicinale e riportato in aggiunta a quelli sollecitati durante lo studio clinico ed a qualsiasi sintomo sollecitato con insorgenza al di fuori il periodo di follow-up specificato per i sintomi sollecitati. Qualsiasi è definito come il verificarsi di eventi avversi spontanei indipendentemente dal grado di intensità o dalla correlazione con la vaccinazione.; 9. Numero di soggetti con eventi avversi seri (SAE) determinati compresi eventi medici che comportano morte, pericolo di vita, causano il ricovero in ospedale o il prolungamento dell'ospedalizzazione o causano disabilità/incapacità.

    11. Numero di soggetti con eventuali patologie immuno-mediate (PIMD) correlate o meno che sono un sottoinsieme di eventi avversi che includono malattie autoimmuni e altri disturbi infiammatori e/o neurologici di interesse che possono o meno avere un'eziologia autoimmune.; 10. Numero di soggetti con SAE correlati al vaccino sperimentale, correlati alla partecipazione allo studio o a vaccini/farmaci concomitanti GSK che comprendono gli eventi medici che comportano la morte, pericolo di vita, causano il ricovero o il prolungamento dell'ospedalizzazione o risultano in disabilità/ incapacità.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1 and 2. 1 month post dose 2 in the previous Z-006/022 studies to study end (Month 72); 3. For the total duration of the Zoster-049 study, i.e. from Month 1 post dose 2 in the previous Z-006/022 studies to study end.; 4 and 5. At months 0, 12, 24, 36, 48, 60 and 72 (LTFU HI and CMI subsets, 1-Add Dose, Revacc and Control groups), and at Month 1 (1-Add Dose, Revacc and Control groups), and at Month 3 (Revacc and Control groups).; 6 and 7. Within 7 days (Days 0-6) after each vaccination.; 8. During the 30 days (Days 0-29) after each vaccination.; 9 and 11. From Month 0 to Month 12 (1-Add Dose and Control groups) and from Month 0 until 12 months after last HZ/su vaccination (Revacc group).; 10. During the entire study (up to Month 72).
    1 e 2.Da 1 mese post dose 2 nei precedenti studi Z-006/022 fino a fine studio (Mese 72); 3. Per l'intera durata dello studio Zoster-049, vale a dire da 1 mese post dose 2 nei precedenti studi Z-006/022 fino a fine studio ; 4 e 5.Ai mesi 0, 12, 24, 36, 48, 60 e 72 (sottogruppi Hl LTFU e CMI, gruppi 1 dose aggiuntiva, rivaccinazione e controllo), e al mese 1 (gruppi 1 dose aggiuntiva, rivaccinazione e controllo) e al mese 3 (gruppi rivaccinazione e controllo).; 6 e 7. Entro 7 giorni (Giorni 0 - 6) dopo ciascuna vaccinazione.; 8. Durante i 30 giorni (Giorni 0 - 29) successivi ciascuna vaccinazione; 9 e 11. Dal Mese 0 al Mese 12 (gruppi controllo e 1 dose aggiuntiva) e dal Mese 0 fino a 12 mesi successivi all'ultima vaccinazione HZ/su (gruppo rivaccinazione); 10. Per l'inter
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    reactogenicity, immunogenicity
    reattogenicità, immunogenicità
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Fattoriale
    Factorial
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Controllo Storico
    Historical Control
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA99
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    Hong Kong
    Japan
    Korea, Republic of
    Mexico
    Taiwan
    United States
    Czechia
    Estonia
    Finland
    France
    Germany
    Italy
    Spain
    Sweden
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Visit Last Subject or Last Contact Last Subject
    Ultima visita ultimo soggetto o ultimo contatto ultimo soggetto
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days10
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1716
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 6865
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state115
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 5458
    F.4.2.2In the whole clinical trial 8581
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    A plan for treatment or care after the subject has ended the
    participation in the trial is not provided for prophylactic vaccine studies, as the subjects are healthy and do not need any treatment or
    care after end of the study.
    Non è fornito nessun trattamento o cura dopo che il soggetto ha concluso la sua partecipazione allo studio dal momento che i soggetti sono sani e non necessitano di alcun trattamento o cura dopo la fine dello studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-09-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-09-07
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-06-28
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 13:16:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA